0H22 Stock Overview
A clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BioInvent International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 47.40 |
| 52 Week High | SEK 47.40 |
| 52 Week Low | SEK 14.60 |
| Beta | 0.33 |
| 11 Month Change | 19.10% |
| 3 Month Change | 24.74% |
| 1 Year Change | 184.75% |
| 33 Year Change | 22.48% |
| 5 Year Change | 23.92% |
| Change since IPO | -92.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0H22 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 4.2% | 4.7% | 1.4% |
| 1Y | 184.8% | -16.4% | 8.1% |
Return vs Industry: 0H22 exceeded the UK Biotechs industry which returned -16.3% over the past year.
Return vs Market: 0H22 exceeded the UK Market which returned 7.9% over the past year.
Price Volatility
| 0H22 volatility | |
|---|---|
| 0H22 Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0H22's share price has been volatile over the past 3 months.
Volatility Over Time: 0H22's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 112 | Martin Welschof | www.bioinvent.com |
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206.
BioInvent International AB (publ) Fundamentals Summary
| 0H22 fundamental statistics | |
|---|---|
| Market cap | SEK 3.15b |
| Earnings (TTM) | -SEK 383.48m |
| Revenue (TTM) | SEK 52.67m |
59.8x
P/S Ratio-8.2x
P/E RatioIs 0H22 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0H22 income statement (TTM) | |
|---|---|
| Revenue | SEK 52.67m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 52.67m |
| Other Expenses | SEK 436.15m |
| Earnings | -SEK 383.48m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 31, 2024
| Earnings per share (EPS) | -5.83 |
| Gross Margin | 100.00% |
| Net Profit Margin | -728.09% |
| Debt/Equity Ratio | 0% |
How did 0H22 perform over the long term?
See historical performance and comparison